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Based on non-hypothesis-driven approaches genetic evi-
dence suggests that diseases are interrelated differently to
our current organ-based ontology. In fact, common effec-
tor mechanisms, when affected or triggered seem to pro-
duce pathophenotypes in diverse organs or co-morbidities.
This will lead eventually to a revised disease nomenclature
and opens up entirely new approaches for diagnosis and
treatment. In this context, we noted that a common cardi-
ovascular target, the cGMP-forming Fe(II) haem protein,
soluble guanylate cyclase (sGC), appears to be situated in
a common mechanism network that is prominently rele-
vant to stroke. Ischemic stroke is the second leading cause
of death worldwide and the leading cause of disability.
Despite this high medical need only a single drug is avail-
able but due to its limited time window and risk of bleed-
ing 85% of all patients are excluded from treatment. As a
possible add-on, vasoactive drugs however typically dilate
normal blood vessels and cause a paradoxical “steal phe-
nomenon” by both shunting blood to healthy vascular
beds and a systemic blood pressure drop. Upon middle
cerebral artery occlusion sGC protein and nitric oxide-
stimulated activity in the ischemic hemisphere were dra-
matically down-regulated leading to a high proportion of
oxidized and/or haem-free apo-sGC activity. Pharmacolo-
gical targeting of apo-sGC in vitro under oxygen and
glucose deprivation conveyed strong neuroprotection via
ERK/CREB signalling. In vivo, post-stroke apo-sGC activa-
tion by two distinct members of this compound class aug-
mented cerebral blood-flow whilst leaving systemic blood
pressure unaffected, reduced infarct size and increased
survival. Different apo-sGC activators are in advanced
stages of clinical development for different cardiovascular
indications. Systems biology and network medicine and
our preliminary target validation suggest that they should
be urgently tested for repurposing as first-in-class,
mechanism-based neuroprotective drugs in stroke.
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